Donald Inadomi
Nephrology · Torrance, CANPI 1154429314
Payments from drug & device makers
Across 252 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$736
- Kowa Pharmaceuticals America, Inc.$658
- Boehringer Ingelheim$624
- Otsuka America Pharmaceutical, Inc.$587
- Bayer$585
- Amgen$408
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,410100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $736 |
| Kowa Pharmaceuticals America, Inc. | 36 | $658 |
| Boehringer Ingelheim | 24 | $624 |
| Otsuka America Pharmaceutical, Inc. | 31 | $587 |
| Bayer | 22 | $585 |
| Amgen(2 entities) | 18 | $408 |
| Vifor Pharma, Inc. | 15 | $312 |
| Lilly USA, LLC | 14 | $274 |
| Aurinia Pharma U.S., Inc. | 10 | $249 |
| Arbor Pharmaceuticals, Inc. | 8 | $153 |
| Calliditas Therapeutics US Inc. | 6 | $138 |
| Mallinckrodt Hospital Products Inc. | 4 | $113 |
| Amarin Pharma, Inc. | 5 | $94 |
| Merck | 5 | $84 |
| OPKO Pharmaceuticals, LLC | 4 | $81 |
| Travere Therapeutics, Inc. | 3 | $55 |
| Ardelyx, Inc. | 2 | $55 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Akebia Therapeutics Inc | 2 | $47 |
| Valeritas, Inc. | 1 | $38 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Novo Nordisk | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
How this compares
$5,427 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 43 | $28,041 |
| Atorvastatin Calcium | 216 | $1,548 |
| SynthroidLevothyroxine Sodium | 13 | $1,358 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 18 | $1,358 |
| Rosuvastatin Calcium | 99 | $1,146 |
| Irbesartan | 57 | $1,007 |
| Potassium Chloride | 22 | $910 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 23 | $853 |
| Amlodipine Besylate | 114 | $643 |
| Valsartan | 18 | $587 |
| Ezetimibe | 24 | $578 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 56 | $567 |
| Simvastatin | 85 | $562 |
| Olmesartan Medoxomil | 19 | $468 |
| Metoprolol Succinate | 25 | $452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $736 | $28,04143 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $20 | $58718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.
Other nephrology in Torrance
- Sharon AdlerTorrance$650K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.